AMFA-targeting technology for advanced medicine
Our purpose is to create new therapies for patients by addressing the drugs to a specific cell compartment, the lysosomes. NanoMedSyn has developed synthetic derivatives of mannose 6-phosphate, called AMFA, that bind the mannose 6-phosphate receptor (M6PR). M6PR is demonstrated as a major pathway for the targeting of proteins bearing M6P or AMFA to lysosomes.
Our AMFA vectors can be conjugated to antibodies, enzymes or nanoparticles and offers a unique solution to unmet clinical needs.
PIPELINE: From one platform to multiple therapeutic areas
- Therapeutic antibodies for antigen degradation
Therapeutic antibodies engineered with AMFA acquire a new capacity to deplete specific soluble and membrane antigens by lysosomal degradation. AMFA-engineered antibodies possess the desirable drug-like features of standard antibodies and AMFA-engineering is compatible with standard manufacturing processes.
This new class of AMFA-engineered antibodies is relevant to the treatment of autoimmune, inflammatory or cancer diseases.
- Enzyme replacement therapy of lysosomal storage diseases
NanoMedSyn has developed acid alpha-glucosidase conjugated with AMFA, aimed for the treatment of Pompe disease. This AMFA engineered enzyme received an orphan drug designation by E.M.A. for enzyme replacement therapy of Pompe patients.
The benefits of AMFA mechanism of action on the enzyme processing up to the lysosome suggest a wider application to other lysosomal storage diseases.
Therapeutic targeting of prostate cancer and rhabdomyosarcoma
NanoMedSyn has demonstrated the capacity of AMFA to target drugs to cancer cells overexpressing the M6PR as it is the case for prostate cancers and rhabdomyosarcoma.Photo credits: fr.freepik.com & NanoMedSyn